511 related articles for article (PubMed ID: 18416147)
21. Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug.
Addeo R; De Santi MS; Del Prete S; Caraglia M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):863-6. PubMed ID: 19639315
[No Abstract] [Full Text] [Related]
22. [Use of nitrosourea compounds in cancer chemotherapy].
Robak T
Pol Tyg Lek; 1982 Sep; 37(36):1067-70. PubMed ID: 6763214
[No Abstract] [Full Text] [Related]
23. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
Beauchesne PD; Taillandier L; Bernier V; Carnin C
Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662
[TBL] [Abstract][Full Text] [Related]
24. Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme.
De Felice F; Bulzonetti N; Musio D; D'Elia A; Salvati M; Tombolini V
Anticancer Res; 2013 Sep; 33(9):4013-6. PubMed ID: 24023343
[TBL] [Abstract][Full Text] [Related]
25. Sterols in cerebrospinal fluid during nitrosourea chemotherapy of human brain tumors.
Fumagalli R; Pezzotta S; Racca AR; Paoletti P
Pharmacol Res Commun; 1976 Apr; 8(2):127-41. PubMed ID: 1028078
[No Abstract] [Full Text] [Related]
26. Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations.
Papavero L; Loew F; Jaksche H
Acta Neurochir (Wien); 1987; 85(3-4):128-37. PubMed ID: 3035882
[TBL] [Abstract][Full Text] [Related]
27. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
Attenello FJ; Mukherjee D; Datoo G; McGirt MJ; Bohan E; Weingart JD; Olivi A; Quinones-Hinojosa A; Brem H
Ann Surg Oncol; 2008 Oct; 15(10):2887-93. PubMed ID: 18636295
[TBL] [Abstract][Full Text] [Related]
28. Medical treatment and other combination regimens.
Bajetta E; Del Vecchio M; Bajetta R; Canova S
Tumori; 2007; 93(3):suppl 22-6. PubMed ID: 17679485
[No Abstract] [Full Text] [Related]
29. [Intra-arterial ACNU chemotherapy of malignant glioma].
Murayama S; Kawai R; Hirabuki N; Miura T; Mitomo M; Kozuka T; Usio Y
Nihon Igaku Hoshasen Gakkai Zasshi; 1988 Feb; 48(2):144-53. PubMed ID: 3164472
[No Abstract] [Full Text] [Related]
30. Adjuvant chemotherapy with nitrosourea compounds following surgery plus radiotherapy in glioblastoma multiforme.
Monfardini S; Brambilla C; Solero CL; Vaghi A; Valagussa P; Morello G; Bonadonna G
Recent Results Cancer Res; 1978; 68():393-8. PubMed ID: 223206
[No Abstract] [Full Text] [Related]
31. Clinical studies in malignant gliomas and their treatment with the nitrosoureas.
Walker MD; Gehan EA
Cancer Treat Rep; 1976 Jun; 60(6):713-6. PubMed ID: 782695
[No Abstract] [Full Text] [Related]
32. PCNU treatment for recurrent malignant gliomas.
Levin VA; Resser KJ; McGrath L; Vestnys P; Nutik S; Wilson CB
Cancer Treat Rep; 1984; 68(7-8):969-73. PubMed ID: 6744348
[No Abstract] [Full Text] [Related]
33. Successful chemotherapy for recurrent malignant oligodendroglioma.
Cairncross JG; Macdonald DR
Ann Neurol; 1988 Apr; 23(4):360-4. PubMed ID: 3382171
[TBL] [Abstract][Full Text] [Related]
34. Lecture: fotemustine in brain tumors.
Silvani A; Gaviani P; Lamperti E; Botturi A; Ferrari D; Simonetti G; Salmaggi A
Neurol Sci; 2011 Nov; 32 Suppl 2():S255-7. PubMed ID: 21987288
[TBL] [Abstract][Full Text] [Related]
35. [Combined treatment of glyal and metastatic tumors of the brain].
Fadeev BP; Zhabina RM
Vestn Khir Im I I Grek; 2005; 164(1):80-2. PubMed ID: 15957817
[TBL] [Abstract][Full Text] [Related]
36. Malignant glioma: who benefits from adjuvant chemotherapy?
DeAngelis LM; Burger PC; Green SB; Cairncross JG
Ann Neurol; 1998 Oct; 44(4):691-5. PubMed ID: 9778271
[TBL] [Abstract][Full Text] [Related]
37. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.
Mangiacavalli S; Pica G; Varettoni M; Lazzarino M; Corso A
Eur J Haematol; 2009 Mar; 82(3):240-1. PubMed ID: 19018860
[No Abstract] [Full Text] [Related]
39. Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center.
Fazeny-Dörner B; Gyries A; Rössler K; Ungersböck K; Czech T; Budinsky A; Killer M; Dieckmann K; Piribauer M; Baumgartner G; Prayer D; Veitl M; Muhm M; Marosi C
Wien Klin Wochenschr; 2003 Jun; 115(11):389-97. PubMed ID: 12879737
[TBL] [Abstract][Full Text] [Related]
40. Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.
Fabi A; Metro G; Vidiri A; Lanzetta G; Carosi M; Telera S; Maschio M; Russillo M; Sperduti I; Carapella CM; Cognetti F; Pace A
J Neurooncol; 2010 Nov; 100(2):209-15. PubMed ID: 20352471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
